title: Comparison of the effects of marchantin C and fucoidan on sFlt-1 and angiogenesis in glioma microenvironment.
abstract: OBJECTIVE
  This study aimed to examine the effects of marchantin C and fucoidan on angiogenesis induced by glioma cells and monocytes, and to elucidate the role of sFlt-1 in this process.
  
  
  METHODS
  T98G glioma cells and THP1 monocytes were pretreated with marchantin C or fucoidan, respectively. Conditioned media were used for endothelial cell tube formation assay and detection of sFlt-1 by ELISA. Depletion of sFlt-1 was achieved by a neutralizing antibody to assess its role in the process.
  
  
  RESULTS
  Marchantin C inhibited angiogenesis induced by T98G cells while fucoidan inhibited both T98G and THP1 cell-induced angiogenesis. In all three groups in which angiogenesis was inhibited, sFlt-1 level in the supernatants was elevated. Pretreatment of the conditioned media with sFlt-1 antibody restored the inhibited angiogenesis to a certain degree.
  
  
  CONCLUSIONS
  This study suggested for the first time that marchantin C and fucoidan could significantly inhibit angiogenesis induced by glioma cells or monocytes. Up-regulation of sFlt-1 played an important role in this process.
authors.affiliation: Department of Neurosurgery Institute of Basic Medical Sciences, Qilu Hospital, Shandong University, China.
authors.forename: Yafeng
authors.initials: Y
authors.lastname: Lv
authors.forename: Qingxu
authors.initials: Q
authors.lastname: Song
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Shao
authors.forename: Wenjuan
authors.initials: W
authors.lastname: Gao
authors.forename: Haiting
authors.initials: H
authors.lastname: Mao
authors.forename: Hongxiang
authors.initials: H
authors.lastname: Lou
authors.forename: Xun
authors.initials: X
authors.lastname: Qu
authors.forename: Xingang
authors.initials: X
authors.lastname: Li
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001632:Bibenzyls / Q000494:pharmacology*; D002460:Cell Line; D045744:Cell Line, Tumor; D004797:Enzyme-Linked Immunosorbent Assay; D005910:Glioma / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D010647:Phenyl Ethers / Q000494:pharmacology*; D011134:Polysaccharides / Q000494:pharmacology*; D059016:Tumor Microenvironment / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D001632:Bibenzyls; D010647:Phenyl Ethers; D011134:Polysaccharides; C459129:marchantin C; C007789:fucoidan; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1